Published in Neurobiol Aging on August 09, 2006
Down syndrome--recent progress and future prospects. Hum Mol Genet (2009) 1.85
Alzheimer's-related endosome dysfunction in Down syndrome is Abeta-independent but requires APP and is reversed by BACE-1 inhibition. Proc Natl Acad Sci U S A (2009) 1.72
Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and down syndrome dementia. J Alzheimers Dis (2010) 1.19
Brain levels of sex steroid hormones in men and women during normal aging and in Alzheimer's disease. Neurobiol Aging (2009) 1.14
Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome. Biochim Biophys Acta (2011) 1.02
BDNF increases with behavioral enrichment and an antioxidant diet in the aged dog. Neurobiol Aging (2010) 0.99
Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia. Curr Gerontol Geriatr Res (2011) 0.98
Peripheral biomarkers in Autism: secreted amyloid precursor protein-alpha as a probable key player in early diagnosis. Int J Clin Exp Med (2008) 0.98
BACE2 expression increases in human neurodegenerative disease. Am J Pathol (2011) 0.95
Plasma amyloid-β as a function of age, level of intellectual disability, and presence of dementia in Down syndrome. J Alzheimers Dis (2011) 0.94
Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology. Curr Alzheimer Res (2016) 0.90
Lifespan profiles of Alzheimer's disease-associated genes and products in monkeys and mice. J Alzheimers Dis (2009) 0.89
NK cells in healthy aging and age-associated diseases. J Biomed Biotechnol (2012) 0.88
Differential gene expression in ADAM10 and mutant ADAM10 transgenic mice. BMC Genomics (2009) 0.88
The GRK2 Overexpression Is a Primary Hallmark of Mitochondrial Lesions during Early Alzheimer Disease. Cardiovasc Psychiatry Neurol (2010) 0.87
Alzheimer's Disease in Down Syndrome. Eur J Neurodegener Dis (2012) 0.85
Quantitative proteomics characterization of a mouse embryonic stem cell model of Down syndrome. Mol Cell Proteomics (2008) 0.82
Reduced neuronal co-localisation of nardilysin and the putative alpha-secretases ADAM10 and ADAM17 in Alzheimer's disease and Down syndrome brains. Age (Dordr) (2008) 0.81
Aβ aggregation profiles and shifts in APP processing favor amyloidogenesis in canines. Neurobiol Aging (2010) 0.80
Late-onset Alzheimer's disease, heating up and foxed by several proteins: pathomolecular effects of the aging process. J Alzheimers Dis (2014) 0.80
The Aqueous Extract of Rhizome of Gastrodia elata Protected Drosophila and PC12 Cells against Beta-Amyloid-Induced Neurotoxicity. Evid Based Complement Alternat Med (2013) 0.79
Transglutaminase activation in neurodegenerative diseases. Future Neurol (2009) 0.79
Drugs for Alzheimer's disease. Br J Clin Pharmacol (2012) 0.79
Molecular and cellular alterations in Down syndrome: toward the identification of targets for therapeutics. Neural Plast (2012) 0.78
Amyloid-modifying therapies for Alzheimer's disease: therapeutic progress and its implications. Age (Dordr) (2010) 0.77
COPS5 protein overexpression increases amyloid plaque burden, decreases spinophilin-immunoreactive puncta, and exacerbates learning and memory deficits in the mouse brain. J Biol Chem (2015) 0.76
Alzheimer's disease: presence and role of microRNAs. Biomol Concepts (2016) 0.75
Insights into cerebrovascular complications and Alzheimer disease through the selective loss of GRK2 regulation. J Cell Mol Med (2008) 0.75
Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE. Science (1999) 13.19
APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy. Nat Genet (2005) 7.66
Brain interleukin 1 and S-100 immunoreactivity are elevated in Down syndrome and Alzheimer disease. Proc Natl Acad Sci U S A (1989) 5.97
Formic acid pretreatment enhances immunostaining of cerebral and systemic amyloids. Lab Invest (1987) 4.98
Dendritic spine abnormalities in amyloid precursor protein transgenic mice demonstrated by gene transfer and intravital multiphoton microscopy. J Neurosci (2005) 4.71
Beta-secretase protein and activity are increased in the neocortex in Alzheimer disease. Arch Neurol (2002) 4.42
Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production. Nat Med (2005) 4.00
Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol (1985) 3.83
Elevated beta-secretase expression and enzymatic activity detected in sporadic Alzheimer disease. Nat Med (2003) 3.78
Abeta42 is essential for parenchymal and vascular amyloid deposition in mice. Neuron (2005) 3.72
Alzheimer's disease: molecular understanding predicts amyloid-based therapeutics. Annu Rev Pharmacol Toxicol (2002) 3.62
Proteolytic processing and cell biological functions of the amyloid precursor protein. J Cell Sci (2000) 3.38
Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease. N Engl J Med (1989) 3.24
Amyloid beta peptide load is correlated with increased beta-secretase activity in sporadic Alzheimer's disease patients. Proc Natl Acad Sci U S A (2004) 2.88
Normal and abnormal biology of the beta-amyloid precursor protein. Annu Rev Neurosci (1994) 2.81
VEGF is necessary for exercise-induced adult hippocampal neurogenesis. Eur J Neurosci (2003) 2.78
Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations. Am J Pathol (2000) 2.78
Presence of soluble amyloid beta-peptide precedes amyloid plaque formation in Down's syndrome. Nat Med (1996) 2.71
Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation. Neurobiol Dis (1996) 2.50
Interleukin-1 expression in different plaque types in Alzheimer's disease: significance in plaque evolution. J Neuropathol Exp Neurol (1995) 2.35
Green tea epigallocatechin-3-gallate (EGCG) modulates amyloid precursor protein cleavage and reduces cerebral amyloidosis in Alzheimer transgenic mice. J Neurosci (2005) 1.99
The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome. J Neurol Sci (1989) 1.95
Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome. Neurobiol Aging (2004) 1.88
Amyloid-beta immunization effectively reduces amyloid deposition in FcRgamma-/- knock-out mice. J Neurosci (2003) 1.87
Intraneuronal abeta-amyloid precedes development of amyloid plaques in Down syndrome. Arch Pathol Lab Med (2001) 1.82
BACE1: the beta-secretase enzyme in Alzheimer's disease. J Mol Neurosci (2004) 1.78
Beta-secretase activity increases with aging in human, monkey, and mouse brain. Am J Pathol (2004) 1.70
The synaptic Abeta hypothesis of Alzheimer disease. Nat Neurosci (2005) 1.68
Regulation of APP cleavage by alpha-, beta- and gamma-secretases. FEBS Lett (2000) 1.65
A prospective study of Alzheimer disease in Down syndrome. Arch Neurol (1989) 1.64
Rab5-stimulated up-regulation of the endocytic pathway increases intracellular beta-cleaved amyloid precursor protein carboxyl-terminal fragment levels and Abeta production. J Biol Chem (2003) 1.60
App gene dosage modulates endosomal abnormalities of Alzheimer's disease in a segmental trisomy 16 mouse model of down syndrome. J Neurosci (2003) 1.59
The pathological association between Down syndrome and Alzheimer disease. Mech Ageing Dev (1988) 1.56
A novel gamma -secretase assay based on detection of the putative C-terminal fragment-gamma of amyloid beta protein precursor. J Biol Chem (2001) 1.55
Coordinated expression of beta-amyloid precursor protein and the putative beta-secretase BACE and alpha-secretase ADAM10 in mouse and human brain. J Neurochem (2000) 1.48
alpha- and beta-secretase: profound changes in Alzheimer's disease. Biochem Biophys Res Commun (2002) 1.37
Expression analysis of BACE2 in brain and peripheral tissues. J Biol Chem (2000) 1.36
Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome. J Neuropathol Exp Neurol (2000) 1.31
Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis. Exp Neurol (1998) 1.24
Age-related distribution of neuropathologic changes in the cerebral cortex of patients with Down's syndrome. Quantitative regional analysis and comparison with Alzheimer's disease. Arch Neurol (1995) 1.22
Presenilin 1 regulates pharmacologically distinct gamma -secretase activities. Implications for the role of presenilin in gamma -secretase cleavage. J Biol Chem (2000) 1.22
Elevated plasma amyloid beta-peptide 1-42 and onset of dementia in adults with Down syndrome. Neurosci Lett (2001) 1.21
Dementia in people with Down's syndrome. Int J Geriatr Psychiatry (2001) 1.20
Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev (2001) 1.20
The C-terminal fragment of the Alzheimer's disease amyloid protein precursor is degraded by a proteasome-dependent mechanism distinct from gamma-secretase. Eur J Biochem (2001) 1.16
Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease. Am J Pathol (2000) 1.13
Region-specific age at onset of beta-amyloid in dogs. Neurobiol Aging (2000) 1.10
Increased plasma amyloid beta protein 1-42 levels in Down syndrome. Neurosci Lett (1998) 1.09
Neuronal RNA oxidation in Alzheimer's disease and Down's syndrome. Ann N Y Acad Sci (1999) 1.05
Amino-terminal modification and tyrosine phosphorylation of [corrected] carboxy-terminal fragments of the amyloid precursor protein in Alzheimer's disease and Down's syndrome brain. Neurobiol Dis (2001) 1.02
Alzheimer beta/A4 amyloid precursor protein in human brain: aging-associated increases in holoprotein and in a proteolytic fragment. Proc Natl Acad Sci U S A (1991) 0.99
Risk factors for dementia in people with down syndrome: issues in assessment and diagnosis. Am J Ment Retard (2004) 0.99
Down syndrome and beta-amyloid deposition. Curr Opin Neurol (2004) 0.98
Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome. Am J Ment Retard (1997) 0.98
Behavioural disturbance in people with Down's syndrome and dementia. J Intellect Disabil Res (1995) 0.97
Proteasome-mediated degradation of the C-terminus of the Alzheimer's disease beta-amyloid protein precursor: effect of C-terminal truncation on production of beta-amyloid protein. J Neurosci Res (2003) 0.95
The gene encoding DRAP (BACE2), a glycosylated transmembrane protein of the aspartic protease family, maps to the down critical region. FEBS Lett (2000) 0.94
Plasma levels of amyloid beta 40 and 42 are independent from ApoE genotype and mental retardation in Down syndrome. Am J Med Genet (2000) 0.92
Precocious aging and dementia in patients with Down's syndrome. Biol Psychiatry (1978) 0.91
Earlier onset of Alzheimer's disease in men with Down syndrome. Neurology (1998) 0.90
Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome. Neurobiol Dis (2001) 0.89
Does Alzheimer disease tilt the scales of amyloid degradation versus accumulation? Nat Med (2000) 0.86
Lymphocyte content of amyloid precursor protein is increased in Down's syndrome and aging. Neurobiol Aging (1997) 0.86
Parallel compensatory and pathological events associated with tau pathology in middle aged individuals with Down syndrome. J Neuropathol Exp Neurol (2003) 0.85
Presenilin-1, amyloid precursor protein and amyloid precursor-like protein 2 mRNA levels in human superior frontal cortex during aging. Neurosci Lett (1997) 0.85
BACE-2 is overexpressed in Down's syndrome. Exp Neurol (2003) 0.84
Elevated expression of beta-site amyloid precursor protein cleaving enzyme 2 in brains of patients with Down syndrome. Neurosci Lett (2002) 0.82
Selective upregulation of the ubiquitin-proteasome proteolytic pathway proteins, proteasome zeta chain and isopeptidase T in fetal Down syndrome. J Neural Transm Suppl (2001) 0.81
Characteristic developmental expression of amyloid beta40, 42 and 43 in patients with Down syndrome. Brain Dev (2003) 0.80
Projections of Alzheimer's disease in the United States and the public health impact of delaying disease onset. Am J Public Health (1998) 9.58
Human blood pressure determination by sphygmomanometry. Circulation (1993) 7.88
Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J (2000) 7.77
Retinoic acid embryopathy. N Engl J Med (1985) 5.85
Risk of Alzheimer's disease and duration of NSAID use. Neurology (1997) 4.06
Estrogen replacement therapy for treatment of mild to moderate Alzheimer disease: a randomized controlled trial. Alzheimer's Disease Cooperative Study. JAMA (2000) 3.99
Studies on ovulation: IV. Induction of ovulation in the hypophysectomized rabbit by administration of anterior lobe extracts. J Physiol (1931) 3.58
Prevalence and ethnic differences in gallbladder disease in the United States. Gastroenterology (1999) 3.55
Clinico-pathologic studies in dementia: nondemented subjects with pathologically confirmed Alzheimer's disease. Neurology (1988) 3.40
Revascularization results in the Interventional Management of Stroke II trial. AJNR Am J Neuroradiol (2008) 3.32
Clinical and pathological evidence for a frontal variant of Alzheimer disease. Arch Neurol (1999) 3.03
Maturation of human central auditory system activity: evidence from multi-channel evoked potentials. Clin Neurophysiol (2000) 2.69
Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Stroke (2001) 2.65
Clinico-neuropathological correlation of Alzheimer's disease in a community-based case series. J Am Geriatr Soc (1999) 2.63
Local opsonization by secreted macrophage complement components. Role of receptors for complement in uptake of zymosan. J Exp Med (1984) 2.53
The multilevel compliance challenge: recommendations for a call to action. A statement for healthcare professionals. Circulation (1997) 2.52
Development of dementing illnesses in an 80-year-old volunteer cohort. Ann Neurol (1989) 2.49
Loss of the presynaptic vesicle protein synaptophysin in hippocampus correlates with cognitive decline in Alzheimer disease. J Neuropathol Exp Neurol (1997) 2.43
A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol (2005) 2.41
An HIV-1 transgenic rat that develops HIV-related pathology and immunologic dysfunction. Proc Natl Acad Sci U S A (2001) 2.28
Prevention of recurrent atrial fibrillation with chronic dual-site right atrial pacing. J Am Coll Cardiol (1996) 2.27
Non-invasive prenatal testing for trisomy 21: a cross-sectional survey of service users' views and likely uptake. BJOG (2014) 2.22
Attitudes of physicians and public to pharmaceutical industry 'gifts'. Intern Med J (2010) 2.20
Validity of the term "family doctor": a limited study in Hamilton, Ontario. Can Med Assoc J (1968) 2.19
Autonomic blocking properties of Wy 21901. Br J Pharmacol (1970) 2.06
Evaluation and outcome measures in the treatment of female urinary stress incontinence: International Urogynecological Association (IUGA) guidelines for research and clinical practice. Int Urogynecol J Pelvic Floor Dysfunct (2007) 1.95
Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovascular and all-cause mortality rates: The Chicago Heart Association Detection Project in Industry Study. Hypertension (2001) 1.94
Retinal haemorrhages in an infant following RetCam screening for retinopathy of prematurity. Eye (Lond) (2004) 1.93
Nonsteroidal anti-inflammatory drugs in Alzheimer's disease. Neurology (1995) 1.92
Free testosterone and risk for Alzheimer disease in older men. Neurology (2004) 1.88
African-American mortality at older ages: results of a matching study. Demography (1996) 1.85
Neuropsychological characteristics of mild cognitive impairment subgroups. J Neurol Neurosurg Psychiatry (2005) 1.83
A new measure of sexual function in women with pelvic floor disorders (PFD): the Pelvic Organ Prolapse/Incontinence Sexual Questionnaire, IUGA-Revised (PISQ-IR). Int Urogynecol J (2013) 1.77
Functions and specificity of T cells following nucleic acid vaccination of mice against Mycobacterium tuberculosis infection. J Immunol (1997) 1.76
National Heart, Lung, and Blood Institute Workshop on Sodium and Blood Pressure : a critical review of current scientific evidence. Hypertension (2000) 1.76
Investigation of the gastrointestinal bacterial flora. Clin Gastroenterol (1978) 1.72
Determinants of vascular dementia in the Cardiovascular Health Cognition Study. Neurology (2005) 1.70
Assessment of low-flow CSF drainage as a treatment for AD: results of a randomized pilot study. Neurology (2002) 1.69
Impact of whooping cough on patients and their families. Br Med J (Clin Res Ed) (1985) 1.68
Mediating the cultural boundaries between medicine, nursing and management--the central challenge in hospital reform. Health Serv Manage Res (2001) 1.61
Expression of TTK, a novel human protein kinase, is associated with cell proliferation. J Biol Chem (1992) 1.59
Virus recovery in chicken cells tested with Rous sarcoma cell DNA. Nat New Biol (1972) 1.57
Clock mutations alter developmental timing in Drosophila. Heredity (Edinb) (1990) 1.53
Should children who use cochlear implants wear hearing aids in the opposite ear? Ear Hear (2001) 1.53
The use of a posterior lip augmentation device for a revision of recurrent dislocation after primary cemented Charnley/Charnley Elite total hip replacement: results at a mean follow-up of six years and nine months. J Bone Joint Surg Br (2007) 1.52
Mitochondria and cell death. Biochem Soc Trans (2000) 1.51
Learning and retention in preclinical and early Alzheimer's disease. Psychol Aging (1997) 1.48
Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association. Circulation (2001) 1.48
Infected pancreatic necrosis and peripancreatic fluid collections: serendipitous response to antibiotics and medical therapy in three patients. Pancreas (1996) 1.47
Dilemmas in the compassionate supply of investigational cancer drugs. Intern Med J (2014) 1.47
Plasticity of hippocampal circuitry in Alzheimer's disease. Science (1985) 1.46
Analysis of the click-evoked brainstem potentials in man unsing high-pass noise masking. J Acoust Soc Am (1978) 1.46
Choledochoduodenostomy: an unjustly maligned surgical procedure? Am J Surg (1970) 1.45
Diet in the aetiology of cancer: a review. Eur J Cancer (1994) 1.45
Intestinal growth-promoting properties of glucagon-like peptide-2 in mice. Am J Physiol (1997) 1.43
[The volumes of the thyroid gland in adults aged 18-65 years in the Czech Republic--determination of the norms]. Vnitr Lek (2006) 1.43
Age-specific norms for the Mini-Mental State Exam. Neurology (1988) 1.42
Late morbidity following nerve-sparing radical hysterectomy. Gynecol Oncol (2009) 1.41
KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood (2000) 1.39
The production of urinary phenols by gut bacteria and their possible role in the causation of large bowel cancer. Am J Clin Nutr (1976) 1.39
Major histocompatibility complex independent clonal T cell anergy by direct interaction of Staphylococcus aureus enterotoxin B with the T cell antigen receptor. J Exp Med (1992) 1.37
Leader protein of encephalomyocarditis virus binds zinc, is phosphorylated during viral infection, and affects the efficiency of genome translation. Virology (2001) 1.37
Recovery of the temperature-sensitive mutant of Rous sarcoma virus from chicken cells exposed to DNA extracted from hamster cells transformed by the mutant. Virology (1972) 1.36
Endotoxin-induced myeloid-derived suppressor cells inhibit alloimmune responses via heme oxygenase-1. Am J Transplant (2009) 1.35
Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol (2001) 1.35
Maturation of human cortical auditory function: differences between normal-hearing children and children with cochlear implants. Ear Hear (1996) 1.33
Comprehensive analysis of karyotypic mosaicism between trophectoderm and inner cell mass. Mol Hum Reprod (2010) 1.29
Quantitative analysis on isolated organs of the autonomic blocking properties of indoramin hydrochloride (Wy 21901). Br J Pharmacol (1972) 1.29
A cross-national study of differences in the identities of nursing in England and Australia and how this has affected nurses' capacity to respond to hospital reform. Nurs Inq (2000) 1.28
Free radicals and the heart. J Pharmacol Toxicol Methods (1993) 1.27
Outcome of occlusion treatment for amblyopia. J Pediatr Ophthalmol Strabismus (1999) 1.27
Female preclinical presenilin-1 mutation carriers unaware of their genetic status have higher levels of depression than their non-mutation carrying kin. J Neurol Neurosurg Psychiatry (2004) 1.27
RNA and DNA forms of the genetic material of C-type viruses and the integrated state of the DNA form in the cellular chromosome. Biochim Biophys Acta (1974) 1.26
Bifunctional role of protein tyrosine kinases in late preconditioning against myocardial stunning in conscious rabbits. Circ Res (2000) 1.26
The importance of language and culture in pediatric care: case studies from the Latino community. J Pediatr (2000) 1.25
Absence of both auditory evoked potentials and auditory percepts dependent on timing cues. Brain (1991) 1.25
Auditory system plasticity in children after long periods of complete deafness. Neuroreport (1996) 1.24
Acute effects of dual-site right atrial pacing in patients with spontaneous and inducible atrial flutter and fibrillation. J Am Coll Cardiol (1997) 1.24
Prevalence of Müllerian duct anomalies detected at ultrasound. Am J Med Genet (2000) 1.24
Learning ability in aged beagle dogs is preserved by behavioral enrichment and dietary fortification: a two-year longitudinal study. Neurobiol Aging (2005) 1.24
Quality estimation of averaged auditory brainstem responses. Scand Audiol (1984) 1.24
Cognitive functions and aging in the dog: acquisition of nonspatial visual tasks. Behav Neurosci (1994) 1.24
Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest (1990) 1.22
Diagnostic validity of the dementia questionnaire for Alzheimer disease. Arch Neurol (1998) 1.22
Dietary enrichment counteracts age-associated cognitive dysfunction in canines. Neurobiol Aging (2002) 1.21
Interferon alpha/beta selectively antagonises down-regulation of mannosyl-fucosyl receptors on activated macrophages by interferon gamma. Biochem Biophys Res Commun (1986) 1.21
Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol (1997) 1.20
Robustness in real life: a study of clinical laboratory data. Biometrics (1982) 1.20
Down syndrome and Alzheimer's disease: a link between development and aging. Ment Retard Dev Disabil Res Rev (2001) 1.20
The cellular pathology of Menkes steely hair syndrome. Neurology (1978) 1.19
Apparent biochemical homozygosity in two obligatory heterozygotes for metachromatic leukodystrophy. J Pediatr (1976) 1.19
Squamous-cell carcinoma of the colon and rectum. Dis Colon Rectum (1983) 1.18
A novel transcriptional unit of the tre oncogene widely expressed in human cancer cells. Oncogene (1992) 1.17
Managing hypertension in the southeastern United States: applying the guidelines from the Sixth Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC VI). Am J Med Sci (1999) 1.17
Prevalence of hepatitis C and G virus infection in chronic hemodialysis patients. Am J Kidney Dis (1998) 1.17
Classification of vascular dementia in the Cardiovascular Health Study Cognition Study. Neurology (2005) 1.17
Vegetarian diet improves insulin resistance and oxidative stress markers more than conventional diet in subjects with Type 2 diabetes. Diabet Med (2011) 1.16
Phase III double-blind evaluation of an aloe vera gel as a prophylactic agent for radiation-induced skin toxicity. Int J Radiat Oncol Biol Phys (1996) 1.16